Fragment-based hit identification: thinking in 3D

Andrew D Morley, Angelo Pugliese, Kristian Birchall, Justin Bower, Paul Brennan, Nathan Brown, Tim Chapman, Martin Drysdale, Ian H Gilbert, Swen Hoelder, Allan Jordan, Steven V Ley, Andy Merritt, David Miller, Martin E Swarbrick, Paul G Wyatt

Research output: Contribution to journalArticlepeer-review


The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

Original languageEnglish
Pages (from-to)1221-7
Number of pages7
JournalDrug discovery today
Issue number23-24
Publication statusPublished - Dec 2013


  • Cooperative Behavior
  • Drug Design
  • Drug Discovery
  • Drug Industry
  • Humans
  • Molecular Conformation
  • Small Molecule Libraries

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Fragment-based hit identification: thinking in 3D'. Together they form a unique fingerprint.

Cite this